Skip to main content
SpringerLink
Log in

Malaria Vaccines

  • Reference work entry
  • First Online:
Infectious Diseases

  • 928 Accesses

  • Originally published in
  • R. A. Meyers (ed.), Encyclopedia of Sustainability Science and Technology, © Springer Science+Business Media, LLC, part of Springer Nature 2022

Glossary

Adjuvant:

A substance added to a vaccine to stimulate a stronger or more effective immune response.

Blood stage:

The stage of the malaria parasite life cycle responsible for clinical symptoms. Vaccines that target the blood stage are intended to prevent disease and death but that do not prevent infection and may not affect malaria transmission.

Challenge trial:

Experimental Phase 1/2 clinical trial in which healthy volunteers receive a malaria vaccine and are exposed to the bites of malaria-infected mosquitoes or injected with malaria parasites under carefully controlled conditions.

Immunogenicity:

The ability of a vaccine to produce specific immune responses (usually antibodies) that recognize the vaccine antigen.

Preerythrocytic:

Stages of the malaria parasite that are injected by a mosquito and develop in the liver before emerging into the blood where they can cause symptoms. Vaccines targeting preerythrocytic stages are intended to prevent infection altogether and, if...

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 299.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Bibliography

Primary Literature

  1. PCC G (1966) Malaria parasites and other haemosporidia, Blackwell, Oxford

    Google Scholar 

  2. World Health O. World Malaria Report. Geneva, Switzerland: World Health Organization, 2020 2020. Report No.

    Google Scholar 

  3. Rieckmann KH (2006) The chequered history of malaria control: are new and better tools the ultimate answer? Ann Trop Med Parasitol 100(8):647–662. https://doi.org/10.1179/136485906X112185

    Article  CAS  Google Scholar 

  4. United Arab Emirates certified malaria-free (2007) Wkly Epidemiol Rec 82(4):30–32

    Google Scholar 

  5. Roberts L, Malaria EM (2007) Did they really say ... Eradication? Science 318(5856):1544–1545. https://doi.org/10.1126/science.318.5856.1544

    Article  CAS  Google Scholar 

  6. Plowe CV, Alonso P, Hoffman SL (2009) The potential role of vaccines in the elimination of falciparum malaria and the eventual eradication of malaria. J Infect Dis 200(11):1646–1649. https://doi.org/10.1086/646613

    Article  Google Scholar 

  7. Henderson DA (1999) Lessons from the eradication campaigns. Vaccine 17(Suppl 3):S53–S55. https://doi.org/10.1016/s0264-410x(99)00293-5

    Article  Google Scholar 

  8. van den Berg M, Ogutu B, Sewankambo NK, Biller-Andorno N, Tanner M (2019) RTS,S malaria vaccine pilot studies: addressing the human realities in large-scale clinical trials. Trials 20(1):316. https://doi.org/10.1186/s13063-019-3391-7

    Article  Google Scholar 

  9. Cox-Singh J, Davis TM, Lee KS, Shamsul SS, Matusop A, Ratnam S, Rahman HA, Conway DJ, Singh B (2008) Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis 46(2):165–171. https://doi.org/10.1086/524888

    Article  CAS  Google Scholar 

  10. Battle KE, Lucas TCD, Nguyen M, Howes RE, Nandi AK, Twohig KA, Pfeffer DA, Cameron E, Rao PC, Casey D, Gibson HS, Rozier JA, Dalrymple U, Keddie SH, Collins EL, Harris JR, Guerra CA, Thorn MP, Bisanzio D, Fullman N, Huynh CK, Kulikoff X, Kutz MJ, Lopez AD, Mokdad AH, Naghavi M, Nguyen G, Shackelford KA, Vos T, Wang H, Lim SS, Murray CJL, Price RN, Baird JK, Smith DL, Bhatt S, Weiss DJ, Hay SI, Gething PW (2019) Mapping the global endemicity and clinical burden of plasmodium vivax, 2000-17: a spatial and temporal modelling study. Lancet 394(10195):332–343. https://doi.org/10.1016/S0140-6736(19)31096-7

    Article  Google Scholar 

  11. mal ERARCPoTfME. (2017) malERA: an updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication. PLoS Med 14(11):e1002455. https://doi.org/10.1371/journal.pmed.1002455

    Article  Google Scholar 

  12. Baruch DI, Pasloske BL, Singh HB, Bi X, Ma XC, Feldman M, Taraschi TF, Howard RJ (1995) Cloning the P. falciparum gene encoding PfEMP1, a malarial variant antigen and adherence receptor on the surface of parasitized human erythrocytes. Cell 82(1):77–87. https://doi.org/10.1016/0092-8674(95)90054-3

    Article  CAS  Google Scholar 

  13. Su XZ, Heatwole VM, Wertheimer SP, Guinet F, Herrfeldt JA, Peterson DS, Ravetch JA, Wellems TE (1995) The large diverse gene family var encodes proteins involved in cytoadherence and antigenic variation of plasmodium falciparum-infected erythrocytes. Cell 82(1):89–100. https://doi.org/10.1016/0092-8674(95)90055-1

    Article  CAS  Google Scholar 

  14. Smith JD, Chitnis CE, Craig AG, Roberts DJ, Hudson-Taylor DE, Peterson DS, Pinches R, Newbold CI, Miller LH (1995) Switches in expression of plasmodium falciparum var genes correlate with changes in antigenic and cytoadherent phenotypes of infected erythrocytes. Cell 82(1):101–110. https://doi.org/10.1016/0092-8674(95)90056-x

    Article  CAS  Google Scholar 

  15. Griffith JW, Sun T, McIntosh MT, Bucala R (2009) Pure Hemozoin is inflammatory in vivo and activates the NALP3 inflammasome via release of uric acid. J Immunol 183(8):5208–5220. https://doi.org/10.4049/jimmunol.0713552

    Article  CAS  Google Scholar 

  16. Nallandhighal S, Park GS, Ho YY, Opoka RO, John CC, Tran TM (2019) Whole-blood transcriptional signatures composed of Erythropoietic and NRF2-regulated genes differ between cerebral Malaria and severe malarial anemia. J Infect Dis 219(1):154–164. https://doi.org/10.1093/infdis/jiy468

    Article  CAS  Google Scholar 

  17. Miller LH, Baruch DI, Marsh K, Doumbo OK (2002) The pathogenic basis of malaria. Nature 415(6872):673–679. https://doi.org/10.1038/415673a

    Article  CAS  Google Scholar 

  18. Seydel KB, Kampondeni SD, Valim C, Potchen MJ, Milner DA, Muwalo FW, Birbeck GL, Bradley WG, Fox LL, Glover SJ, Hammond CA, Heyderman RS, Chilingulo CA, Molyneux ME, Taylor TE (2015) Brain swelling and death in children with cerebral malaria. N Engl J Med 372(12):1126–1137. https://doi.org/10.1056/NEJMoa1400116

    Article  CAS  Google Scholar 

  19. MacCormick IJ, Beare NA, Taylor TE, Barrera V, White VA, Hiscott P, Molyneux ME, Dhillon B, Harding SP (2014) Cerebral malaria in children: using the retina to study the brain. Brain 137(Pt 8):2119–2142. https://doi.org/10.1093/brain/awu001

    Article  Google Scholar 

  20. Moxon CA, Wassmer SC, Milner DA Jr, Chisala NV, Taylor TE, Seydel KB, Molyneux ME, Faragher B, Esmon CT, Downey C, Toh CH, Craig AG, Heyderman RS (2013) Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children. Blood 122(5):842–851. https://doi.org/10.1182/blood-2013-03-490219

    Article  CAS  Google Scholar 

  21. Lavstsen T, Turner L, Saguti F, Magistrado P, Rask TS, Jespersen JS, Wang CW, Berger SS, Baraka V, Marquard AM, Seguin-Orlando A, Willerslev E, Gilbert MT, Lusingu J, Theander TG (2012) Plasmodium falciparum erythrocyte membrane protein 1 domain cassettes 8 and 13 are associated with severe malaria in children. Proc Natl Acad Sci U S A 109(26):E1791–E1800. https://doi.org/10.1073/pnas.1120455109

    Article  Google Scholar 

  22. Storm J, Jespersen JS, Seydel KB, Szestak T, Mbewe M, Chisala NV, Phula P, Wang CW, Taylor TE, Moxon CA, Lavstsen T, Craig AG (2019) Cerebral malaria is associated with differential cytoadherence to brain endothelial cells. EMBO Mol Med 11(2). https://doi.org/10.15252/emmm.201809164

  23. Fried M, Duffy PE (1996) Adherence of plasmodium falciparum to chondroitin sulfate a in the human placenta. Science 272(5267):1502–1504. https://doi.org/10.1126/science.272.5267

    Article  CAS  Google Scholar 

  24. Nash GB, O'Brien E, Gordon-Smith EC, Dormandy JA (1989) Abnormalities in the mechanical properties of red blood cells caused by plasmodium falciparum. Blood 74(2):855–861

    Article  CAS  Google Scholar 

  25. Herricks T, Antia M, Rathod PK (2009) Deformability limits of plasmodium falciparum-infected red blood cells. Cell Microbiol 11(9):1340–1353. https://doi.org/10.1111/j.1462-5822.2009.01334.x

    Article  CAS  Google Scholar 

  26. Gupta S, Snow RW, Donnelly CA, Marsh K, Newbold C (1999) Immunity to non-cerebral severe malaria is acquired after one or two infections. Nat Med 5(3):340–343. https://doi.org/10.1038/6560

    Article  CAS  Google Scholar 

  27. Hviid L (2005) Naturally acquired immunity to plasmodium falciparum malaria in Africa. Acta Trop 95(3):270–275. https://doi.org/10.1016/j.actatropica.2005.06.012

    Article  Google Scholar 

  28. Ricke CH, Staalsoe T, Koram K, Akanmori BD, Riley EM, Theander TG, Hviid L (2000) Plasma antibodies from malaria-exposed pregnant women recognize variant surface antigens on plasmodium falciparum-infected erythrocytes in a parity-dependent manner and block parasite adhesion to chondroitin sulfate a. J Immunol 165(6):3309–3316. https://doi.org/10.4049/jimmunol.165.6.3309

    Article  CAS  Google Scholar 

  29. Baird JK, Jones TR, Danudirgo EW, Annis BA, Bangs MJ, Basri H, Purnomo MS (1991) Age-dependent acquired protection against plasmodium falciparum in people having two years exposure to hyperendemic malaria. Am J Trop Med Hyg. 45(1):65–76. https://doi.org/10.4269/ajtmh.1991.45.65

    Article  CAS  Google Scholar 

  30. Amaratunga C, Lopera-Mesa TM, Brittain NJ, Cholera R, Arie T, Fujioka H, Keefer JR, Fairhurst RM (2011) A role for fetal hemoglobin and maternal immune IgG in infant resistance to plasmodium falciparum malaria. PLoS One 6(4):e14798. https://doi.org/10.1371/journal.pone.0014798

    Article  CAS  Google Scholar 

  31. Ceesay SJ, Koivogui L, Nahum A, Taal MA, Okebe J, Affara M, Kaman LE, Bohissou F, Agbowai C, Tolno BG, Amambua-Ngwa A, Bangoura NF, Ahounou D, Muhammad AK, Duparc S, Hamed K, Ubben D, Bojang K, Achan J, D'Alessandro U (2015) Malaria prevalence among Young infants in different transmission settings. Africa Emerg Infect Dis 21(7):1114–1121. https://doi.org/10.3201/eid2107.142036

    Article  CAS  Google Scholar 

  32. Snow RW, Gilles HM (2017) The epidemiology of malaria. Essential malariology. CRC Press, pp 85–106

    Google Scholar 

  33. Cotter C, Sturrock HJW, Hsiang MS, Liu J, Phillips AA, Hwang J, Gueye CS, Fullman N, Gosling RD, Feachem RGA (2013) The changing epidemiology of malaria elimination: new strategies for new challenges. Lancet 382(9895):900–911. https://doi.org/10.1016/S0140-6736(13)60310-4

    Article  Google Scholar 

  34. Duffy PE (2007) Plasmodium in the placenta: parasites, parity, protection, prevention and possibly preeclampsia. Parasitology 134(Pt 13):1877–1881. https://doi.org/10.1017/S0031182007000170

    Article  CAS  Google Scholar 

  35. Rabinovich RN, Drakeley C, Djimde AA, Hall BF, Hay SI, Hemingway J, Kaslow DC, Noor A, Okumu F, Steketee R, Tanner M, Wells TNC, Whittaker MA, Winzeler EA, Wirth DF, Whitfield K, Alonso PL (2017) malERA: an updated research agenda for malaria elimination and eradication. PLoS Med 14(11):e1002456. https://doi.org/10.1371/journal.pmed.1002456

    Article  Google Scholar 

  36. Cohen S, Mc GI, Carrington S (1961) Gamma-globulin and acquired immunity to human malaria. Nature 192:733–737. https://doi.org/10.1038/192733a0

    Article  CAS  Google Scholar 

  37. McGregor IA, Carrington SP, Cohen S (1963) Treatment of east african P. falciparum malaria with west african human γ-globulin. Trans R Soc Trop Med Hyg 57(3):170–175. https://doi.org/10.1016/0035-9203(63)90058-0

    Article  Google Scholar 

  38. Collins WE, Jeffery GM (1999) A retrospective examination of sporozoite- and trophozoite-induced infections with plasmodium falciparum in patients previously infected with heterologous species of plasmodium: effect on development of parasitologic and clinical immunity. Am J Trop Med Hyg. 61(1 Suppl):36–43. https://doi.org/10.4269/tropmed.1999.61-036

    Article  CAS  Google Scholar 

  39. Collins WE, Jeffery GM (1999) A retrospective examination of secondary sporozoite- and trophozoite-induced infections with plasmodium falciparum: development of parasitologic and clinical immunity following secondary infection. Am J Trop Med Hyg. 61(1 Suppl):20–35. https://doi.org/10.4269/tropmed.1999.61-020

    Article  CAS  Google Scholar 

  40. Thomas AW, Trape JF, Rogier C, Goncalves A, Rosario VE, Narum DL (1994) High prevalence of natural antibodies against plasmodium falciparum 83-kilodalton apical membrane antigen (PF83/AMA-1) as detected by capture-enzyme-linked immunosorbent assay using full-length baculovirus recombinant PF83/AMA-1. Am J Trop Med Hyg. 51(6):730–740. https://doi.org/10.4269/ajtmh.1994.51.730

    Article  CAS  Google Scholar 

  41. Egan AF, Chappel JA, Burghaus PA, Morris JS, McBride JS, Holder AA, Kaslow DC, Riley EM (1995) Serum antibodies from malaria-exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP1(19), the carboxy-terminal fragment of the major merozoite surface protein of plasmodium falciparum. Infect Immun 63(2):456–466. https://doi.org/10.1128/IAI.63.2.456-466.1995

    Article  CAS  Google Scholar 

  42. Schofield L (1989) T cell immunity to malaria sporozoites. Exp Parasitol 68(3):357–364. https://doi.org/10.1016/0014-4894(89)90118-5

    Article  CAS  Google Scholar 

  43. MalariaGen AA, Ali M, Almagro-Garcia J, Amambua-Ngwa A, Amaratunga C, Amato R, Amenga-Etego L, Andagalu B, Anderson TJC, Andrianaranjaka V, Apinjoh T, Ariani C, Ashley EA, Auburn S, Awandare G, Ba H, Baraka V, Barry AE, Bejon P, Bertin GI, Boni MF, Borrmann S, Bousema T, Branch O, Bull PC, Busby GBJ, Chookajorn T, Chotivanich K, Claessens A, Conway D, Craig A, D'Alessandro U, Dama S, Day NP, Denis B, Diakite M, Djimde A, Dolecek C, Dondorp AM, Drakeley C, Drury E, Duffy P, Echeverry DF, Egwang TG, Erko B, Fairhurst RM, Faiz A, Fanello CA, Fukuda MM, Gamboa D, Ghansah A, Golassa L, Goncalves S, Hamilton WL, Harrison GLA, Hart L, Henrichs C, Hien TT, Hill CA, Hodgson A, Hubbart C, Imwong M, Ishengoma DS, Jackson SA, Jacob CG, Jeffery B, Jeffreys AE, Johnson KJ, Jyothi D, Kamaliddin C, Kamau E, Kekre M, Kluczynski K, Kochakarn T, Konate A, Kwiatkowski DP, Kyaw MP, Lim P, Lon C, Loua KM, Maiga-Ascofare O, Malangone C, Manske M, Marfurt J, Marsh K, Mayxay M, Miles A, Miotto O, Mobegi V, Mokuolu OA, Montgomery J, Mueller I, Newton PN, Nguyen T, Nguyen TN, Noedl H, Nosten F, Noviyanti R, Nzila A, Ochola-Oyier LI, Ocholla H, Oduro A, Omedo I, Onyamboko MA, Ouedraogo JB, Oyebola K, Pearson RD, Peshu N, Phyo AP, Plowe CV, Price RN, Pukrittayakamee S, Randrianarivelojosia M, Rayner JC, Ringwald P, Rockett KA, Rowlands K, Ruiz L, Saunders D, Shayo A, Siba P, Simpson VJ, Stalker J, Su XZ, Sutherland C, Takala-Harrison S, Tavul L, Thathy V, Tshefu A, Verra F, Vinetz J, Wellems TE, Wendler J, White NJ, Wright I, Yavo W, Ye H (2021) An open dataset of plasmodium falciparum genome variation in 7,000 worldwide samples. Wellcome Open Res 6:42. https://doi.org/10.12688/wellcomeopenres.16168.1

    Article  CAS  Google Scholar 

  44. Bradwell KR, Coulibaly D, Kone AK, Laurens MB, Dembele A, Tolo Y, Traore K, Niangaly A, Berry AA, Kouriba B, Plowe CV, Doumbo OK, Lyke KE, Takala-Harrison S, Thera MA, Travassos MA, Serre D (2020) Host and parasite transcriptomic changes upon successive plasmodium falciparum infections in early childhood. mSystems 5(4). https://doi.org/10.1128/mSystems.00116-20

  45. Neafsey DE, Juraska M, Bedford T, Benkeser D, Valim C, Griggs A, Lievens M, Abdulla S, Adjei S, Agbenyega T, Agnandji ST, Aide P, Anderson S, Ansong D, Aponte JJ, Asante KP, Bejon P, Birkett AJ, Bruls M, Connolly KM, D'Alessandro U, Dobano C, Gesase S, Greenwood B, Grimsby J, Tinto H, Hamel MJ, Hoffman I, Kamthunzi P, Kariuki S, Kremsner PG, Leach A, Lell B, Lennon NJ, Lusingu J, Marsh K, Martinson F, Molel JT, Moss EL, Njuguna P, Ockenhouse CF, Ogutu BR, Otieno W, Otieno L, Otieno K, Owusu-Agyei S, Park DJ, Pelle K, Robbins D, Russ C, Ryan EM, Sacarlal J, Sogoloff B, Sorgho H, Tanner M, Theander T, Valea I, Volkman SK, Yu Q, Lapierre D, Birren BW, Gilbert PB, Wirth DF (2015) Genetic diversity and protective efficacy of the RTS,S/AS01 Malaria vaccine. N Engl J Med 373(21):2025–2037. https://doi.org/10.1056/NEJMoa1505819

    Article  CAS  Google Scholar 

  46. Doolan DL, Mu Y, Unal B, Sundaresh S, Hirst S, Valdez C, Randall A, Molina D, Liang X, Freilich DA, Oloo JA, Blair PL, Aguiar JC, Baldi P, Davies DH, Felgner PL (2008) Profiling humoral immune responses to P. falciparum infection with protein microarrays. Proteomics 8(22):4680–4694. https://doi.org/10.1002/pmic.200800194

    Article  CAS  Google Scholar 

  47. Crompton PD, Kayala MA, Traore B, Kayentao K, Ongoiba A, Weiss GE, Molina DM, Burk CR, Waisberg M, Jasinskas A, Tan X, Doumbo S, Doumtabe D, Kone Y, Narum DL, Liang X, Doumbo OK, Miller LH, Doolan DL, Baldi P, Felgner PL, Pierce SK (2010) A prospective analysis of the ab response to plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci U S A 107(15):6958–6963. https://doi.org/10.1073/pnas.1001323107

    Article  Google Scholar 

  48. Bailey JA, Berry AA, Travassos MA, Ouattara A, Boudova S, Dotsey EY, Pike A, Jacob CG, Adams M, Tan JC, Bannen RM, Patel JJ, Pablo J, Nakajima R, Jasinskas A, Dutta S, Takala-Harrison S, Lyke KE, Laurens MB, Niangaly A, Coulibaly D, Kouriba B, Doumbo OK, Thera MA, Felgner PL, Plowe CV (2020) Microarray analyses reveal strain-specific antibody responses to plasmodium falciparum apical membrane antigen 1 variants following natural infection and vaccination. Sci Rep 10(1):3952. https://doi.org/10.1038/s41598-020-60551-z

    Article  CAS  Google Scholar 

  49. Allison AC (1954) Protection afforded by sickle-cell trait against subtertian malareal infection. Br Med J 1(4857):290–294. https://doi.org/10.1136/bmj.1.4857.290

    Article  CAS  Google Scholar 

  50. Kay AC, Kuhl W, Prchal J, Beutler E (1992) The origin of glucose-6-phosphate-dehydrogenase (G6PD) polymorphisms in African-Americans. Am J Hum Genet 50(2):394–398

    CAS  Google Scholar 

  51. Agarwal A, Guindo A, Cissoko Y, Taylor JG, Coulibaly D, Kone A, Kayentao K, Djimde A, Plowe CV, Doumbo O, Wellems TE, Diallo D (2000) Hemoglobin C associated with protection from severe malaria in the Dogon of Mali, a west African population with a low prevalence of hemoglobin S. Blood 96(7):2358–2363

    Article  CAS  Google Scholar 

  52. Flint J, Hill AV, Bowden DK, Oppenheimer SJ, Sill PR, Serjeantson SW, Bana-Koiri J, Bhatia K, Alpers MP, Boyce AJ et al (1986) High frequencies of alpha-thalassaemia are the result of natural selection by malaria. Nature 321(6072):744–750. https://doi.org/10.1038/321744a0

    Article  CAS  Google Scholar 

  53. Travassos MA, Coulibaly D, Laurens MB, Dembele A, Tolo Y, Kone AK, Traore K, Niangaly A, Guindo A, Wu Y, Berry AA, Jacob CG, Takala-Harrison S, Adams M, Shrestha B, Mu AZ, Kouriba B, Lyke KE, Diallo DA, Doumbo OK, Plowe CV, Thera MA (2015) Hemoglobin C trait provides protection from clinical falciparum Malaria in Malian children. J Infect Dis 212(11):1778–1786. https://doi.org/10.1093/infdis/jiv308

    Article  CAS  Google Scholar 

  54. Hill AV, Allsopp CE, Kwiatkowski D, Anstey NM, Twumasi P, Rowe PA, Bennett S, Brewster D, McMichael AJ, Greenwood BM (1991) Common west African HLA antigens are associated with protection from severe malaria. Nature 352(6336):595–600. https://doi.org/10.1038/352595a0

    Article  CAS  Google Scholar 

  55. Miller LH, Mason SJ, Clyde DF, McGinniss MH (1976) The resistance factor to plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N Engl J Med 295(6):302–304. https://doi.org/10.1056/NEJM197608052950602

    Article  CAS  Google Scholar 

  56. Malaria Genomic Epidemiology Network (2019) Insights into malaria susceptibility using genome-wide data on 17,000 individuals from Africa, Asia and Oceania. Nat Commun 10(1):5732. https://doi.org/10.1038/s41467-019-13480-z

    Article  CAS  Google Scholar 

  57. Bruce-Chwatt LJ (1981) Alphonse Laveran's discovery 100 years ago and today's global fight against malaria. J R Soc Med 74(7):531–536

    Article  CAS  Google Scholar 

  58. Ross R (1883) Observations on a condition necessary to the transformation of the Malaria crescent. Br Med J 1897(1):251–255. https://doi.org/10.1136/bmj.1.1883.251

    Article  Google Scholar 

  59. Russell PF, Mohan BN (1942) The immunization of fowls against mosquito-borne plasmodium Gallinaceum by injections of serum and of inactivated homologous Sporozoites. J Exp Med 76 (5):477–495. https://doi.org/10.1084/jem.76.5.477

    Article  CAS  Google Scholar 

  60. Freund J, Sommer HE, Walter AW (1945) Immunization against Malaria: vaccination of ducks with killed parasites incorporated with adjuvants. Science 102(2643):200–202. https://doi.org/10.1126/science.102.2643.200

    Article  CAS  Google Scholar 

  61. Freund J, Thomson KJ, Sommer HE, Walter AW, Schenkein EL (1945) Immunization of rhesus monkeys against malarial infection (P. Knowlesi) with killed parasites and adjuvants. Science 102(2643):202–204. https://doi.org/10.1126/science.102.2643.202

    Article  CAS  Google Scholar 

  62. Jacobs HR (1943) Increased protection by vaccination of ducklings with insoluble residues of plasmodium lophurae mixed with a bacterial toxin. Am J Trop Med Hyg (s1–23, 6):597–606. https://doi.org/10.4269/ajtmh.1943.s1-23.597

  63. Redmond WB (1939) Immunization of birds to malaria by vaccination. J Parasitol 25:28–29

    Google Scholar 

  64. Bennison BE, Coatney GR (1949) Effects of X-irradiation on plasmodium gallinaceum and plasmodium lophurae infections in young chicks. J Natl Malar Soc 8(4):280–289

    CAS  Google Scholar 

  65. Ceithaml J, Evans EA Jr (1946) The biochemistry of the malaria parasite; the in vitro effects of x-rays upon plasmodium gallinaceum. J Infect Dis 78:190–197. https://doi.org/10.1093/infdis/78.3.190

    Article  CAS  Google Scholar 

  66. Nussenzweig R, Vanderberg J, Most H (1969) Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei. IV. Dose response, specificity and humoral immunity. Mil Med 134(10):1176–1182

    Article  CAS  Google Scholar 

  67. Hoffman SL, Billingsley PF, James E, Richman A, Loyevsky M, Li T, Chakravarty S, Gunasekera A, Chattopadhyay R, Li M, Stafford R, Ahumada A, Epstein JE, Sedegah M, Reyes S, Richie TL, Lyke KE, Edelman R, Laurens MB, Plowe CV, Sim BK (2010) Development of a metabolically active, non-replicating sporozoite vaccine to prevent plasmodium falciparum malaria. Hum Vaccin 6(1):97–106. https://doi.org/10.4161/hv.6.1.10396

    Article  CAS  Google Scholar 

  68. Heidelberger M, Prout C et al (1946) Studies in human malaria; an attempt at vaccination of paretics against blood-borne infection with Pl. vivax. J Immunol 53:109–112

    Article  CAS  Google Scholar 

  69. Clyde DF, Most H, McCarthy VC, Vanderberg JP (1973) Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci 266(3):169–177

    Article  CAS  Google Scholar 

  70. Rieckmann KH, Carson PE, Beaudoin RL, Cassells JS, Sell KW (1974) Letter: Sporozoite induced immunity in man against an Ethiopian strain of plasmodium falciparum. Trans R Soc Trop Med Hyg 68(3):258–259. https://doi.org/10.1016/0035-9203(74)90129-1

    Article  CAS  Google Scholar 

  71. Luke TC, Hoffman SL (2003) Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated plasmodium falciparum sporozoite vaccine. J Exp Biol 206(Pt 21):3803–3808. https://doi.org/10.1242/jeb.00644

    Article  Google Scholar 

  72. Vanderberg JP (2009) Reflections on early malaria vaccine studies, the first successful human malaria vaccination, and beyond. Vaccine 27(1):2–9. https://doi.org/10.1016/j.vaccine.2008.10.028

    Article  CAS  Google Scholar 

  73. Trager W, Jensen JB (2005) Human malaria parasites in continuous culture. 1976. J Parasitol 91(3):484–486. https://doi.org/10.1645/0022-3395(2005)091[0484:HMPICC]2.0.CO;2

    Article  Google Scholar 

  74. Haynes JD, Diggs CL, Hines FA, Desjardins RE (1976) Culture of human malaria parasites plasmodium falciparum. Nature 263(5580):767–769. https://doi.org/10.1038/263767a0

    Article  CAS  Google Scholar 

  75. Laurens MB (2018) The promise of a Malaria vaccine-are we closer? Annu Rev Microbiol 72:273–292. https://doi.org/10.1146/annurev-micro-090817-062427

    Article  CAS  Google Scholar 

  76. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A, Nelson KE, Bowman S, Paulsen IT, James K, Eisen JA, Rutherford K, Salzberg SL, Craig A, Kyes S, Chan MS, Nene V, Shallom SJ, Suh B, Peterson J, Angiuoli S, Pertea M, Allen J, Selengut J, Haft D, Mather MW, Vaidya AB, Martin DM, Fairlamb AH, Fraunholz MJ, Roos DS, Ralph SA, McFadden GI, Cummings LM, Subramanian GM, Mungall C, Venter JC, Carucci DJ, Hoffman SL, Newbold C, Davis RW, Fraser CM, Barrell B (2002) Genome sequence of the human malaria parasite plasmodium falciparum. Nature 419(6906):498–511. https://doi.org/10.1038/nature01097

    Article  CAS  Google Scholar 

  77. Takala SL, Plowe CV (2009) Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'. Parasite Immunol 31(9):560–573. https://doi.org/10.1111/j.1365-3024.2009.01138.x

    Article  CAS  Google Scholar 

  78. Takala SL, Coulibaly D, Thera MA, Dicko A, Smith DL, Guindo AB, Kone AK, Traore K, Ouattara A, Djimde AA, Sehdev PS, Lyke KE, Diallo DA, Doumbo OK, Plowe CV (2007) Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in Mali. PLoS Med 4(3):e93. https://doi.org/10.1371/journal.pmed.0040093

    Article  Google Scholar 

  79. Takala SL, Coulibaly D, Thera MA, Batchelor AH, Cummings MP, Escalante AA, Ouattara A, Traore K, Niangaly A, Djimde AA, Doumbo OK, Plowe CV (2009) Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Sci Transl Med 1(2):2ra5. https://doi.org/10.1126/scitranslmed.3000257

    Article  CAS  Google Scholar 

  80. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, Mandomando I, Spiessens B, Guinovart C, Espasa M, Bassat Q, Aide P, Ofori-Anyinam O, Navia MM, Corachan S, Ceuppens M, Dubois MC, Demoitie MA, Dubovsky F, Menendez C, Tornieporth N, Ballou WR, Thompson R, Cohen J (2004) Efficacy of the RTS,S/AS02A vaccine against plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364(9443):1411–1420. https://doi.org/10.1016/S0140-6736(04)17223-1

    Article  CAS  Google Scholar 

  81. Rts SCTP, Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, Kabwende AL, Adegnika AA, Mordmuller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Machevo S, Acacio S, Bulo H, Sigauque B, Macete E, Alonso P, Abdulla S, Salim N, Minja R, Mpina M, Ahmed S, Ali AM, Mtoro AT, Hamad AS, Mutani P, Tanner M, Tinto H, D'Alessandro U, Sorgho H, Valea I, Bihoun B, Guiraud I, Kabore B, Sombie O, Guiguemde RT, Ouedraogo JB, Hamel MJ, Kariuki S, Oneko M, Odero C, Otieno K, Awino N, McMorrow M, Muturi-Kioi V, Laserson KF, Slutsker L, Otieno W, Otieno L, Otsyula N, Gondi S, Otieno A, Owira V, Oguk E, Odongo G, Woods JB, Ogutu B, Njuguna P, Chilengi R, Akoo P, Kerubo C, Maingi C, Lang T, Olotu A, Bejon P, Marsh K, Mwambingu G, Owusu-Agyei S, Asante KP, Osei-Kwakye K, Boahen O, Dosoo D, Asante I, Adjei G, Kwara E, Chandramohan D, Greenwood B, Lusingu J, Gesase S, Malabeja A, Abdul O, Mahende C, Liheluka E, Malle L, Lemnge M, Theander TG, Drakeley C, Ansong D, Agbenyega T, Adjei S, Boateng HO, Rettig T, Bawa J, Sylverken J, Sambian D, Sarfo A, Agyekum A, Martinson F, Hoffman I, Mvalo T, Kamthunzi P, Nkomo R, Tembo T, Tegha G, Tsidya M, Kilembe J, Chawinga C, Ballou WR, Cohen J, Guerra Y, Jongert E, Lapierre D, Leach A, Lievens M, Ofori-Anyinam O, Olivier A, Vekemans J, Carter T, Kaslow D, Leboulleux D, Loucq C, Radford A, Savarese B, Schellenberg D, Sillman M, Vansadia P (2012) A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 367(24):2284–2295. https://doi.org/10.1056/NEJMoa1208394

    Article  CAS  Google Scholar 

  82. Egan AF, Blackman MJ, Kaslow DC (2000) Vaccine efficacy of recombinant plasmodium falciparum merozoite surface protein 1 in malaria-naive, −exposed, and/or -rechallenged Aotus vociferans monkeys. Infect Immun 68(3):1418–1427. https://doi.org/10.1128/iai.68.3.1418-1427.2000

    Article  CAS  Google Scholar 

  83. Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Sagara I, Dicko A, Diemert DJ, Heppner DG Jr, Stewart VA, Angov E, Soisson L, Leach A, Tucker K, Lyke KE, Plowe CV, Mali FMPWG (2006) Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial. PLoS Clin Trials 1(7):e34. https://doi.org/10.1371/journal.pctr.0010034

    Article  CAS  Google Scholar 

  84. Stoute JA, Gombe J, Withers MR, Siangla J, McKinney D, Onyango M, Cummings JF, Milman J, Tucker K, Soisson L, Stewart VA, Lyon JA, Angov E, Leach A, Cohen J, Kester KE, Ockenhouse CF, Holland CA, Diggs CL, Wittes J, Heppner DG Jr (2007) Group MSPMVW. Phase 1 randomized double-blind safety and immunogenicity trial of plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. Vaccine 25(1):176–184. https://doi.org/10.1016/j.vaccine.2005.11.037

    Article  CAS  Google Scholar 

  85. Withers MR, McKinney D, Ogutu BR, Waitumbi JN, Milman JB, Apollo OJ, Allen OG, Tucker K, Soisson LA, Diggs C, Leach A, Wittes J, Dubovsky F, Stewart VA, Remich SA, Cohen J, Ballou WR, Holland CA, Lyon JA, Angov E, Stoute JA, Martin SK, Heppner DG Jr, Group MSPMVW (2006) Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children. PLoS Clin Trials. 1(7):e32. https://doi.org/10.1371/journal.pctr.0010032

    Article  CAS  Google Scholar 

  86. Ogutu BR, Apollo OJ, McKinney D, Okoth W, Siangla J, Dubovsky F, Tucker K, Waitumbi JN, Diggs C, Wittes J, Malkin E, Leach A, Soisson LA, Milman JB, Otieno L, Holland CA, Polhemus M, Remich SA, Ockenhouse CF, Cohen J, Ballou WR, Martin SK, Angov E, Stewart VA, Lyon JA, Heppner DG, Withers MR, Group MSPMVW (2009) Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS One 4(3):e4708. https://doi.org/10.1371/journal.pone.0004708

    Article  CAS  Google Scholar 

  87. Sagara I, Dicko A, Ellis RD, Fay MP, Diawara SI, Assadou MH, Sissoko MS, Kone M, Diallo AI, Saye R, Guindo MA, Kante O, Niambele MB, Miura K, Mullen GE, Pierce M, Martin LB, Dolo A, Diallo DA, Doumbo OK, Miller LH, Saul A (2009) A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine 27(23):3090–3098. https://doi.org/10.1016/j.vaccine.2009.03.014

    Article  CAS  Google Scholar 

  88. Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Kone AK, Guindo AB, Traore K, Dicko A, Sagara I, Sissoko MS, Baby M, Sissoko M, Diarra I, Niangaly A, Dolo A, Daou M, Diawara SI, Heppner DG, Stewart VA, Angov E, Bergmann-Leitner ES, Lanar DE, Dutta S, Soisson L, Diggs CL, Leach A, Owusu A, Dubois MC, Cohen J, Nixon JN, Gregson A, Takala SL, Lyke KE, Plowe CV (2008) Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial. PLoS One 3(1):e1465. https://doi.org/10.1371/journal.pone.0001465

    Article  Google Scholar 

  89. Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Kone AK, Guindo AB, Traore K, Sissoko M, Diallo DA, Diarra I, Kouriba B, Daou M, Dolo A, Baby M, Sissoko MS, Sagara I, Niangaly A, Traore I, Olotu A, Godeaux O, Leach A, Dubois MC, Ballou WR, Cohen J, Thompson D, Dube T, Soisson L, Diggs CL, Takala SL, Lyke KE, House B, Lanar DE, Dutta S, Heppner DG, Plowe CV (2010) Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial. PLoS One 5(2):e9041. https://doi.org/10.1371/journal.pone.0009041

    Article  CAS  Google Scholar 

  90. Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Ouattara A, Kone AK, Guindo AB, Traore K, Traore I, Kouriba B, Diallo DA, Diarra I, Daou M, Dolo A, Tolo Y, Sissoko MS, Niangaly A, Sissoko M, Takala-Harrison S, Lyke KE, Wu Y, Blackwelder WC, Godeaux O, Vekemans J, Dubois MC, Ballou WR, Cohen J, Thompson D, Dube T, Soisson L, Diggs CL, House B, Lanar DE, Dutta S, Heppner DG Jr, Plowe CV (2011) A field trial to assess a blood-stage malaria vaccine. N Engl J Med 365(11):1004–1013. https://doi.org/10.1056/NEJMoa1008115

    Article  CAS  Google Scholar 

  91. Dame JB, Williams JL, McCutchan TF, Weber JL, Wirtz RA, Hockmeyer WT, Maloy WL, Haynes JD, Schneider I, Roberts D et al (1984) Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite plasmodium falciparum. Science 225(4662):593–599. https://doi.org/10.1126/science.6204383

    Article  CAS  Google Scholar 

  92. Beier JCV, J.P. (1998) Sporogonic development in the mosquito, Washington, DC

    Google Scholar 

  93. Ballou WR, Rothbard J, Wirtz RA, Gordon DM, Williams JS, Gore RW, Schneider I, Hollingdale MR, Beaudoin RL, Maloy WL et al (1985) Immunogenicity of synthetic peptides from circumsporozoite protein of plasmodium falciparum. Science 228(4702):996–999. https://doi.org/10.1126/science.2988126

    Article  CAS  Google Scholar 

  94. Hollingdale MR, Nardin EH, Tharavanij S, Schwartz AL, Nussenzweig RS (1984) Inhibition of entry of plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies. J Immunol 132(2):909–913

    Article  CAS  Google Scholar 

  95. Herrington DA, Clyde DF, Losonsky G, Cortesia M, Murphy JR, Davis J, Baqar S, Felix AM, Heimer EP, Gillessen D et al (1987) Safety and immunogenicity in man of a synthetic peptide malaria vaccine against plasmodium falciparum sporozoites. Nature 328(6127):257–259. https://doi.org/10.1038/328257a0

    Article  CAS  Google Scholar 

  96. Ballou WR, Hoffman SL, Sherwood JA, Hollingdale MR, Neva FA, Hockmeyer WT, Gordon DM, Schneider I, Wirtz RA, Young JF et al (1987) Safety and efficacy of a recombinant DNA plasmodium falciparum sporozoite vaccine. Lancet 1(8545):1277–1281. https://doi.org/10.1016/s0140-6736(87)90540-x

    Article  CAS  Google Scholar 

  97. Hoffman SL, Oster CN, Plowe CV, Woollett GR, Beier JC, Chulay JD, Wirtz RA, Hollingdale MR, Mugambi M (1987) Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. Science 237(4815):639–642. https://doi.org/10.1126/science.3299709

    Article  CAS  Google Scholar 

  98. Sherwood JA, Copeland RS, Taylor KA, Abok K, Oloo AJ, Were JB, Strickland GT, Gordon DM, Ballou WR, Bales JD Jr, Wirtz RA, Wittes J, Gross M, Que JU, Cryz SJ, Oster CN, Roberts CR, Sadoff JC (1996) Plasmodium falciparum circumsporozoite vaccine immunogenicity and efficacy trial with natural challenge quantitation in an area of endemic human malaria of Kenya. Vaccine 14(8):817–827. https://doi.org/10.1016/0264-410x(95)00221-l

    Article  CAS  Google Scholar 

  99. Gordon DM, McGovern TW, Krzych U, Cohen JC, Schneider I, LaChance R, Heppner DG, Yuan G, Hollingdale M, Slaoui M et al (1995) Safety, immunogenicity, and efficacy of a recombinantly produced plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis 171(6):1576–1585. https://doi.org/10.1093/infdis/171.6.1576

    Article  CAS  Google Scholar 

  100. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, Wellde BT, Garcon N, Krzych U, Marchand M (1997) A preliminary evaluation of a recombinant circumsporozoite protein vaccine against plasmodium falciparum malaria. RTS,S Malaria vaccine evaluation group. N Engl J Med 336(2):86–91. https://doi.org/10.1056/NEJM199701093360202

    Article  CAS  Google Scholar 

  101. Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, Hall T, Krzych U, Delchambre M, Voss G, Dowler MG, Palensky J, Wittes J, Cohen J, Ballou WR, Rts SMVEG (2001) Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental plasmodium falciparum malaria. J Infect Dis 183(4):640–647. https://doi.org/10.1086/318534

    Article  CAS  Google Scholar 

  102. Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, Ballou WR, Conway DJ, Reece WH, Gothard P, Yamuah L, Delchambre M, Voss G, Greenwood BM, Hill A, McAdam KP, Tornieporth N, Cohen JD, Doherty T, Rts SMVTT (2001) Efficacy of RTS,S/AS02 malaria vaccine against plasmodium falciparum infection in semi-immune adult men in the Gambia: a randomised trial. Lancet 358(9297):1927–1934. https://doi.org/10.1016/S0140-6736(01)06957-4

    Article  CAS  Google Scholar 

  103. Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, Mshamu S, Lang T, Gould J, Dubois MC, Demoitie MA, Stallaert JF, Vansadia P, Carter T, Njuguna P, Awuondo KO, Malabeja A, Abdul O, Gesase S, Mturi N, Drakeley CJ, Savarese B, Villafana T, Ballou WR, Cohen J, Riley EM, Lemnge MM, Marsh K, von Seidlein L (2008) Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 359(24):2521–2532. https://doi.org/10.1056/NEJMoa0807381

    Article  CAS  Google Scholar 

  104. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Aide P, Sigauque B, Milman J, Mandomando I, Bassat Q, Guinovart C, Espasa M, Corachan S, Lievens M, Navia MM, Dubois MC, Menendez C, Dubovsky F, Cohen J, Thompson R, Ballou WR (2005) Duration of protection with RTS,S/AS02A malaria vaccine in prevention of plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366(9502):2012–2018. https://doi.org/10.1016/S0140-6736(05)67669-6

    Article  CAS  Google Scholar 

  105. Sacarlal J, Aide P, Aponte JJ, Renom M, Leach A, Mandomando I, Lievens M, Bassat Q, Lafuente S, Macete E, Vekemans J, Guinovart C, Sigauque B, Sillman M, Milman J, Dubois MC, Demoitie MA, Thonnard J, Menendez C, Ballou WR, Cohen J, Alonso PL (2009) Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children. J Infect Dis 200(3):329–336. https://doi.org/10.1086/600119

    Article  Google Scholar 

  106. Rts SCTP (2015) Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386(9988):31–45. https://doi.org/10.1016/S0140-6736(15)60721-8

    Article  CAS  Google Scholar 

  107. Regules JA, Cicatelli SB, Bennett JW, Paolino KM, Twomey PS, Moon JE, Kathcart AK, Hauns KD, Komisar JL, Qabar AN, Davidson SA, Dutta S, Griffith ME, Magee CD, Wojnarski M, Livezey JR, Kress AT, Waterman PE, Jongert E, Wille-Reece U, Volkmuth W, Emerling D, Robinson WH, Lievens M, Morelle D, Lee CK, Yassin-Rajkumar B, Weltzin R, Cohen J, Paris RM, Waters NC, Birkett AJ, Kaslow DC, Ballou WR, Ockenhouse CF, Vekemans J (2016) Fractional third and fourth dose of RTS,S/AS01 Malaria candidate vaccine: a phase 2a controlled human Malaria parasite infection and immunogenicity study. J Infect Dis 214(5):762–771. https://doi.org/10.1093/infdis/jiw237

    Article  CAS  Google Scholar 

  108. Collins KA, Snaith R, Cottingham MG, Gilbert SC, Hill AVS (2017) Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. Sci Rep 7:46621. https://doi.org/10.1038/srep46621

    Article  CAS  Google Scholar 

  109. Cummings JF, Spring MD, Schwenk RJ, Ockenhouse CF, Kester KE, Polhemus ME, Walsh DS, Yoon IK, Prosperi C, Juompan LY, Lanar DE, Krzych U, Hall BT, Ware LA, Stewart VA, Williams J, Dowler M, Nielsen RK, Hillier CJ, Giersing BK, Dubovsky F, Malkin E, Tucker K, Dubois MC, Cohen JD, Ballou WR, Heppner DG Jr (2010) Recombinant liver stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental plasmodium falciparum infection. Vaccine 28(31):5135–5144. https://doi.org/10.1016/j.vaccine.2009.08.046

    Article  CAS  Google Scholar 

  110. Ewer KJ, Sierra-Davidson K, Salman AM, Illingworth JJ, Draper SJ, Biswas S, Hill AV (2015) Progress with viral vectored malaria vaccines: a multi-stage approach involving "unnatural immunity". Vaccine 33(52):7444–7451. https://doi.org/10.1016/j.vaccine.2015.09.094

    Article  CAS  Google Scholar 

  111. Chuang I, Sedegah M, Cicatelli S, Spring M, Polhemus M, Tamminga C, Patterson N, Guerrero M, Bennett JW, McGrath S, Ganeshan H, Belmonte M, Farooq F, Abot E, Banania JG, Huang J, Newcomer R, Rein L, Litilit D, Richie NO, Wood C, Murphy J, Sauerwein R, Hermsen CC, McCoy AJ, Kamau E, Cummings J, Komisar J, Sutamihardja A, Shi M, Epstein JE, Maiolatesi S, Tosh D, Limbach K, Angov E, Bergmann-Leitner E, Bruder JT, Doolan DL, King CR, Carucci D, Dutta S, Soisson L, Diggs C, Hollingdale MR, Ockenhouse CF, Richie TL (2013) DNA prime/adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One 8(2):e55571. https://doi.org/10.1371/journal.pone.0055571

    Article  CAS  Google Scholar 

  112. Kurtovic L, Wetzel D, Reiling L, Drew DR, Palmer C, Kouskousis B, Hanssen E, Wines BD, Hogarth PM, Suckow M, Jenzelewski V, Piontek M, Chan JA, Beeson JG (2021) Novel virus-like particle vaccine encoding the Circumsporozoite protein of plasmodium falciparum is immunogenic and induces functional antibody responses in mice. Front Immunol 12:641421. https://doi.org/10.3389/fimmu.2021.641421

    Article  CAS  Google Scholar 

  113. Kisalu NK, Idris AH, Weidle C, Flores-Garcia Y, Flynn BJ, Sack BK, Murphy S, Schon A, Freire E, Francica JR, Miller AB, Gregory J, March S, Liao HX, Haynes BF, Wiehe K, Trama AM, Saunders KO, Gladden MA, Monroe A, Bonsignori M, Kanekiyo M, Wheatley AK, McDermott AB, Farney SK, Chuang GY, Zhang B, Kc N, Chakravarty S, Kwong PD, Sinnis P, Bhatia SN, Kappe SHI, Sim BKL, Hoffman SL, Zavala F, Pancera M, Seder RA (2018) A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat Med 24(4):408–416. https://doi.org/10.1038/nm.4512

    Article  CAS  Google Scholar 

  114. Wang LT, Pereira LS, Flores-Garcia Y, O'Connor J, Flynn BJ, Schon A, Hurlburt NK, Dillon M, Yang ASP, Fabra-Garcia A, Idris AH, Mayer BT, Gerber MW, Gottardo R, Mason RD, Cavett N, Ballard RB, Kisalu NK, Molina-Cruz A, Nelson J, Vistein R, Barillas-Mury C, Amino R, Baker D, King NP, Sauerwein RW, Pancera M, Cockburn IA, Zavala F, Francica JR, Seder RA (2020) A potent anti-malarial human monoclonal antibody targets Circumsporozoite protein minor repeats and neutralizes Sporozoites in the liver. Immunity 53(4):733–44 e8. https://doi.org/10.1016/j.immuni.2020.08.014

    Article  CAS  Google Scholar 

  115. Francica JR, Shi W, Chuang GY, Chen SJ, Da Silva PL, Farney SK, Flynn BJ, Ou L, Stephens T, Tsybovsky Y, Wang LT, Anderson A, Beck Z, Dillon M, Idris AH, Hurlburt N, Liu T, Zhang B, Alving CR, Matyas GR, Pancera M, Mascola JR, Kwong PD, Seder RA (2021) Design of Alphavirus Virus-like Particles Presenting Circumsporozoite Junctional Epitopes that Elicit Protection against Malaria. Vaccines (Basel) 9(3). https://doi.org/10.3390/vaccines9030272

  116. Knockel J, Dundas K, Yang ASP, Galaway F, Metcalf T, Gemert GV, Sauerwein RW, Rayner JC, Billker O, Wright GJ (2021) Systematic identification of plasmodium falciparum Sporozoite membrane protein interactions reveals an essential role for the p24 complex in host infection. Mol Cell Proteomics 20:100038. https://doi.org/10.1074/mcp.RA120.002432

    Article  CAS  Google Scholar 

  117. Blackman MJ, Heidrich HG, Donachie S, McBride JS, Holder AA (1990) A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. J Exp Med 172(1):379–382. https://doi.org/10.1084/jem.172.1.379

    Article  CAS  Google Scholar 

  118. Egan AF, Morris J, Barnish G, Allen S, Greenwood BM, Kaslow DC, Holder AA, Riley EM (1996) Clinical immunity to plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J Infect Dis 173(3):765–769. https://doi.org/10.1093/infdis/173.3.765

    Article  CAS  Google Scholar 

  119. Riley EM, Allen SJ, Wheeler JG, Blackman MJ, Bennett S, Takacs B, Schonfeld HJ, Holder AA, Greenwood BM (1992) Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of plasmodium falciparum are associated with reduced malaria morbidity. Parasite Immunol 14(3):321–337. https://doi.org/10.1111/j.1365-3024.1992.tb00471.x

    Article  CAS  Google Scholar 

  120. Stowers AW, Cioce V, Shimp RL, Lawson M, Hui G, Muratova O, Kaslow DC, Robinson R, Long CA, Miller LH (2001) Efficacy of two alternate vaccines based on plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial. Infect Immun 69(3):1536–1546. https://doi.org/10.1128/IAI.69.3.1536-1546.2001

    Article  CAS  Google Scholar 

  121. Narum DL, Thomas AW (1994) Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of plasmodium falciparum merozoites. Mol Biochem Parasitol 67(1):59–68. https://doi.org/10.1016/0166-6851(94)90096-5

    Article  CAS  Google Scholar 

  122. Mitchell GH, Thomas AW, Margos G, Dluzewski AR, Bannister LH (2004) Apical membrane antigen 1, a major malaria vaccine candidate, mediates the close attachment of invasive merozoites to host red blood cells. Infect Immun 72(1):154–158. https://doi.org/10.1128/iai.72.1.154-158.2004

    Article  CAS  Google Scholar 

  123. Florens L, Washburn MP, Raine JD, Anthony RM, Grainger M, Haynes JD, Moch JK, Muster N, Sacci JB, Tabb DL, Witney AA, Wolters D, Wu Y, Gardner MJ, Holder AA, Sinden RE, Yates JR, Carucci DJ (2002) A proteomic view of the plasmodium falciparum life cycle. Nature 419(6906):520–526. https://doi.org/10.1038/nature01107

    Article  CAS  Google Scholar 

  124. Hodder AN, Crewther PE, Anders RF (2001) Specificity of the protective antibody response to apical membrane antigen 1. Infect Immun 69(5):3286–3294. https://doi.org/10.1128/IAI.69.5.3286-3294.2001

    Article  CAS  Google Scholar 

  125. Polley SD, Mwangi T, Kocken CH, Thomas AW, Dutta S, Lanar DE, Remarque E, Ross A, Williams TN, Mwambingu G, Lowe B, Conway DJ, Marsh K (2004) Human antibodies to recombinant protein constructs of plasmodium falciparum apical membrane antigen 1 (AMA1) and their associations with protection from malaria. Vaccine 23(5):718–728. https://doi.org/10.1016/j.vaccine.2004.05.031

    Article  CAS  Google Scholar 

  126. Dutta S, Lee SY, Batchelor AH, Lanar DE (2007) Structural basis of antigenic escape of a malaria vaccine candidate. Proc Natl Acad Sci U S A 104(30):12488–12493. https://doi.org/10.1073/pnas.0701464104

    Article  CAS  Google Scholar 

  127. Healer J, Murphy V, Hodder AN, Masciantonio R, Gemmill AW, Anders RF, Cowman AF, Batchelor A (2004) Allelic polymorphisms in apical membrane antigen-1 are responsible for evasion of antibody-mediated inhibition in plasmodium falciparum. Mol Microbiol 52(1):159–168. https://doi.org/10.1111/j.1365-2958.2003.03974.x

    Article  CAS  Google Scholar 

  128. Ouattara A, Mu J, Takala-Harrison S, Saye R, Sagara I, Dicko A, Niangaly A, Duan J, Ellis RD, Miller LH, Su XZ, Plowe CV, Doumbo OK (2010) Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine. Malar J 9:175. https://doi.org/10.1186/1475-2875-9-175

    Article  CAS  Google Scholar 

  129. Spring MD, Cummings JF, Ockenhouse CF, Dutta S, Reidler R, Angov E, Bergmann-Leitner E, Stewart VA, Bittner S, Juompan L, Kortepeter MG, Nielsen R, Krzych U, Tierney E, Ware LA, Dowler M, Hermsen CC, Sauerwein RW, de Vlas SJ, Ofori-Anyinam O, Lanar DE, Williams JL, Kester KE, Tucker K, Shi M, Malkin E, Long C, Diggs CL, Soisson L, Dubois MC, Ballou WR, Cohen J, Heppner DG Jr (2009) Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS One 4(4):e5254. https://doi.org/10.1371/journal.pone.0005254

    Article  CAS  Google Scholar 

  130. Remarque EJ, Faber BW, Kocken CH, Thomas AW (2008) A diversity-covering approach to immunization with plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits. Infect Immun 76(6):2660–2670. https://doi.org/10.1128/IAI.00170-08

    Article  CAS  Google Scholar 

  131. Remarque EJ, Faber BW, Kocken CH, Thomas AW (2008) Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol 24(2):74–84. https://doi.org/10.1016/j.pt.2007.12.002

    Article  CAS  Google Scholar 

  132. Dutta S, Dlugosz LS, Clayton JW, Pool CD, Haynes JD, Gasser RA 3rd, Batchelor AH (2010) Alanine mutagenesis of the primary antigenic escape residue cluster, c1, of apical membrane antigen 1. Infect Immun 78(2):661–671. https://doi.org/10.1128/IAI.00866-09

    Article  CAS  Google Scholar 

  133. Sirima SB, Durier C, Kara L, Houard S, Gansane A, Loulergue P, Bahuaud M, Benhamouda N, Nebie I, Faber B, Remarque E, Launay O, Group AM-DS (2017) Safety and immunogenicity of a recombinant plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel(R) in European and African adults: a phase 1a/1b, randomized, double-blind multi-Centre trial. Vaccine 35(45):6218–6227. https://doi.org/10.1016/j.vaccine.2017.09.027

    Article  CAS  Google Scholar 

  134. Douglas AD, Williams AR, Illingworth JJ, Kamuyu G, Biswas S, Goodman AL, Wyllie DH, Crosnier C, Miura K, Wright GJ, Long CA, Osier FH, Marsh K, Turner AV, Hill AV, Draper SJ (2011) The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat Commun 2:601. https://doi.org/10.1038/ncomms1615

    Article  CAS  Google Scholar 

  135. Payne RO, Silk SE, Elias SC, Miura K, Diouf A, Galaway F, de Graaf H, Brendish NJ, Poulton ID, Griffiths OJ, Edwards NJ, Jin J, Labbe GM, Alanine DG, Siani L, Di Marco S, Roberts R, Green N, Berrie E, Ishizuka AS, Nielsen CM, Bardelli M, Partey FD, Ofori MF, Barfod L, Wambua J, Murungi LM, Osier FH, Biswas S, McCarthy JS, Minassian AM, Ashfield R, Viebig NK, Nugent FL, Douglas AD, Vekemans J, Wright GJ, Faust SN, Hill AV, Long CA, Lawrie AM, Draper SJ (2017) Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. JCI. Insight 2(21). https://doi.org/10.1172/jci.insight.96381

  136. Ragotte RJ, Higgins MK, Draper SJ (2020) The RH5-CyRPA-Ripr complex as a Malaria vaccine target. Trends Parasitol 36(6):545–559. https://doi.org/10.1016/j.pt.2020.04.003

    Article  CAS  Google Scholar 

  137. Raj DK, Nixon CP, Nixon CE, Dvorin JD, DiPetrillo CG, Pond-Tor S, Wu HW, Jolly G, Pischel L, Lu A, Michelow IC, Cheng L, Conteh S, McDonald EA, Absalon S, Holte SE, Friedman JF, Fried M, Duffy PE, Kurtis JD (2014) Antibodies to PfSEA-1 block parasite egress from RBCs and protect against malaria infection. Science 344(6186):871–877. https://doi.org/10.1126/science.1254417

    Article  CAS  Google Scholar 

  138. Kurtis JD, Raj DK, Michelow IC, Park S, Nixon CE, McDonald EA, Nixon CP, Pond-Tor S, Jha A, Taliano RJ, Kabyemela ER, Friedman JF, Duffy PE, Fried M (2019) Maternally-derived antibodies to Schizont egress Antigen-1 and protection of infants from severe Malaria. Clin Infect Dis 68(10):1718–1724. https://doi.org/10.1093/cid/ciy728

    Article  CAS  Google Scholar 

  139. Klein MM, Gittis AG, Su HP, Makobongo MO, Moore JM, Singh S, Miller LH, Garboczi DN (2008) The cysteine-rich interdomain region from the highly variable plasmodium falciparum erythrocyte membrane protein-1 exhibits a conserved structure. PLoS Pathog 4(9):e1000147. https://doi.org/10.1371/journal.ppat.1000147

    Article  CAS  Google Scholar 

  140. Salanti A, Dahlback M, Turner L, Nielsen MA, Barfod L, Magistrado P, Jensen AT, Lavstsen T, Ofori MF, Marsh K, Hviid L, Theander TG (2004) Evidence for the involvement of VAR2CSA in pregnancy-associated malaria. J Exp Med 200(9):1197–1203. https://doi.org/10.1084/jem.20041579

    Article  CAS  Google Scholar 

  141. Ampomah P, Stevenson L, Ofori MF, Barfod L, Hviid L (2014) Kinetics of B cell responses to plasmodium falciparum erythrocyte membrane protein 1 in Ghanaian women naturally exposed to malaria parasites. J Immunol 192(11):5236–5244. https://doi.org/10.4049/jimmunol.1400325

    Article  CAS  Google Scholar 

  142. Chene A, Houard S, Nielsen MA, Hundt S, D'Alessio F, Sirima SB, Luty AJ, Duffy P, Leroy O, Gamain B, Viebig NK (2016) Clinical development of placental malaria vaccines and immunoassays harmonization: a workshop report. Malar J 15:476. https://doi.org/10.1186/s12936-016-1527-8

    Article  Google Scholar 

  143. Sirima SB, Richert L, Chene A, Konate AT, Campion C, Dechavanne S, Semblat JP, Benhamouda N, Bahuaud M, Loulergue P, Ouedraogo A, Nebie I, Kabore M, Kargougou D, Barry A, Ouattara SM, Boilet V, Allais F, Roguet G, Havelange N, Lopez-Perez E, Kuppers A, Konate E, Roussillon C, Kante M, Belarbi L, Diarra A, Henry N, Soulama I, Ouedraogo A, Esperou H, Leroy O, Batteux F, Tartour E, Viebig NK, Thiebaut R, Launay O, Gamain B (2020) PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study. Lancet Infect Dis 20(5):585–597. https://doi.org/10.1016/S1473-3099(19)30739-X

    Article  CAS  Google Scholar 

  144. Mordmuller B, Sulyok M, Egger-Adam D, Resende M, de Jongh WA, Jensen MH, Smedegaard HH, Ditlev SB, Soegaard M, Poulsen L, Dyring C, Calle CL, Knoblich A, Ibanez J, Esen M, Deloron P, Ndam N, Issifou S, Houard S, Howard RF, Reed SG, Leroy O, Luty AJF, Theander TG, Kremsner PG, Salanti A, Nielsen MA (2019) First-in-human, randomized, double-blind clinical trial of differentially Adjuvanted PAMVAC, a vaccine candidate to prevent pregnancy-associated Malaria. Clin Infect Dis 69(9):1509–1516. https://doi.org/10.1093/cid/ciy1140

    Article  CAS  Google Scholar 

  145. Verity R, Hathaway NJ, Waltmann A, Doctor SM, Watson OJ, Patel JC, Mwandagalirwa K, Tshefu AK, Bailey JA, Ghani AC, Juliano JJ, Meshnick SR (2018) Plasmodium falciparum genetic variation of var2csa in the Democratic Republic of the Congo. Malar J 17(1):46. https://doi.org/10.1186/s12936-018-2193-9

    Article  Google Scholar 

  146. Barr PJ, Green KM, Gibson HL, Bathurst IC, Quakyi IA, Kaslow DC (1991) Recombinant Pfs25 protein of plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. J Exp Med 174(5):1203–1208. https://doi.org/10.1084/jem.174.5.1203

    Article  CAS  Google Scholar 

  147. Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, Fay MP, Narum D, Rausch K, Miles AP, Aebig J, Orcutt A, Muratova O, Song G, Lambert L, Zhu D, Miura K, Long C, Saul A, Miller LH, Durbin AP (2008) Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One 3(7):e2636. https://doi.org/10.1371/journal.pone.0002636

    Article  Google Scholar 

  148. Chichester JA, Green BJ, Jones RM, Shoji Y, Miura K, Long CA, Lee CK, Ockenhouse CF, Morin MJ, Streatfield SJ, Yusibov V (2018) Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: a phase 1 dose-escalation study in healthy adults. Vaccine 36(39):5865–5871. https://doi.org/10.1016/j.vaccine.2018.08.033

    Article  CAS  Google Scholar 

  149. Sagara I, Healy SA, Assadou MH, Gabriel EE, Kone M, Sissoko K, Tembine I, Guindo MA, Doucoure M, Niare K, Dolo A, Rausch KM, Narum DL, Jones DL, MacDonald NJ, Zhu D, Mohan R, Muratova O, Baber I, Coulibaly MB, Fay MP, Anderson C, Wu Y, Traore SF, Doumbo OK, Duffy PE (2018) Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults. Lancet Infect Dis 18(9):969–982. https://doi.org/10.1016/S1473-3099(18)30344-X

    Article  CAS  Google Scholar 

  150. Armistead JS, Morlais I, Mathias DK, Jardim JG, Joy J, Fridman A, Finnefrock AC, Bagchi A, Plebanski M, Scorpio DG, Churcher TS, Borg NA, Sattabongkot J, Dinglasan RR (2014) Antibodies to a single, conserved epitope in anopheles APN1 inhibit universal transmission of plasmodium falciparum and plasmodium vivax malaria. Infect Immun 82(2):818–829. https://doi.org/10.1128/IAI.01222-13

    Article  CAS  Google Scholar 

  151. Bender NG, Khare P, Martinez J, Tweedell RE, Nyasembe VO, Lopez-Gutierrez B, Tripathi A, Miller D, Hamerly T, Vela EM, Davis RR, Howard RF, Nsango S, Cobb RR, Harbers M, Dinglasan RR (2021) Immunofocusing humoral immunity potentiates the functional efficacy of the AnAPN1 malaria transmission-blocking vaccine antigen. NPJ Vaccines. 6(1):49. https://doi.org/10.1038/s41541-021-00309-4

    Article  CAS  Google Scholar 

  152. Theisen M, Roeffen W, Singh SK, Andersen G, Amoah L, van de Vegte-Bolmer M, Arens T, Tiendrebeogo RW, Jones S, Bousema T, Adu B, Dziegiel MH, Christiansen M, Sauerwein R (2014) A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages. Vaccine 32(22):2623–2630. https://doi.org/10.1016/j.vaccine.2014.03.020

    Article  CAS  Google Scholar 

  153. Lee SM, Hickey JM, Miura K, Joshi SB, Volkin DB, King CR, Plieskatt JL (2020) A C-terminal Pfs48/45 malaria transmission-blocking vaccine candidate produced in the baculovirus expression system. Sci Rep 10(1):395. https://doi.org/10.1038/s41598-019-57384-w

    Article  CAS  Google Scholar 

  154. Healy SA, Anderson C, Swihart BJ, Mwakingwe A, Gabriel EE, Decederfelt H, Hobbs CV, Rausch KM, Zhu D, Muratova O, Herrera R, Scaria PV, MacDonald NJ, Lambert LE, Zaidi I, Coelho CH, Renn JP, Wu Y, Narum DL, Duffy PE (2021) Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice. J Clin Invest 131(7). https://doi.org/10.1172/JCI146221

  155. Canepa GE, Molina-Cruz A, Yenkoidiok-Douti L, Calvo E, Williams AE, Burkhardt M, Peng F, Narum D, Boulanger MJ, Valenzuela JG, Barillas-Mury C (2018) Antibody targeting of a specific region of Pfs47 blocks plasmodium falciparum malaria transmission. NPJ Vaccines 3:26. https://doi.org/10.1038/s41541-018-0065-5

    Article  CAS  Google Scholar 

  156. Molina-Cruz A, Canepa GE, Alves ESTL, Williams AE, Nagyal S, Yenkoidiok-Douti L, Nagata BM, Calvo E, Andersen J, Boulanger MJ, Barillas-Mury C (2020) Plasmodium falciparum evades immunity of anopheline mosquitoes by interacting with a Pfs47 midgut receptor. Proc Natl Acad Sci U S A 117(5):2597–2605. https://doi.org/10.1073/pnas.1917042117

    Article  CAS  Google Scholar 

  157. Dinglasan RR, Valenzuela JG, Azad AF (2005) Sugar epitopes as potential universal disease transmission blocking targets. Insect Biochem Mol Biol 35(1):1–10. https://doi.org/10.1016/j.ibmb.2004.09.005

    Article  CAS  Google Scholar 

  158. Valero MV, Amador LR, Galindo C, Figueroa J, Bello MS, Murillo LA, Mora AL, Patarroyo G, Rocha CL, Rojas M et al (1993) Vaccination with SPf66, a chemically synthesised vaccine, against plasmodium falciparum malaria in Colombia. Lancet 341(8847):705–710. https://doi.org/10.1016/0140-6736(93)90483-w

    Article  CAS  Google Scholar 

  159. Nosten F, Luxemburger C, Kyle DE, Ballou WR, Wittes J, Wah E, Chongsuphajaisiddhi T, Gordon DM, White NJ, Sadoff JC, Heppner DG (1996) Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria vaccine trial group. Lancet 348(9029):701–707. https://doi.org/10.1016/s0140-6736(96)04465-0

    Article  CAS  Google Scholar 

  160. D'Alessandro U, Leach A, Drakeley CJ, Bennett S, Olaleye BO, Fegan GW, Jawara M, Langerock P, George MO, Targett GA et al (1995) Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet 346(8973):462–467. https://doi.org/10.1016/s0140-6736(95)91321-1

    Article  CAS  Google Scholar 

  161. Alonso PL, Smith T, Schellenberg JR, Masanja H, Mwankusye S, Urassa H, Bastos de Azevedo I, Chongela J, Kobero S, Menendez C et al (1994) Randomised trial of efficacy of SPf66 vaccine against plasmodium falciparum malaria in children in southern Tanzania. Lancet 344(8931):1175–1181. https://doi.org/10.1016/s0140-6736(94)90505-3

    Article  CAS  Google Scholar 

  162. Ockenhouse CF, Sun PF, Lanar DE, Wellde BT, Hall BT, Kester K, Stoute JA, Magill A, Krzych U, Farley L, Wirtz RA, Sadoff JC, Kaslow DC, Kumar S, Church LW, Crutcher JM, Wizel B, Hoffman S, Lalvani A, Hill AV, Tine JA, Guito KP, de Taisne C, Anders R, Ballou WR et al (1998) Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for plasmodium falciparum malaria. J Infect Dis 177(6):1664–1673. https://doi.org/10.1086/515331

    Article  CAS  Google Scholar 

  163. Kumar S, Epstein JE, Richie TL, Nkrumah FK, Soisson L, Carucci DJ, Hoffman SL (2002) A multilateral effort to develop DNA vaccines against falciparum malaria. Trends Parasitol 18(3):129–135. https://doi.org/10.1016/s1471-4922(01)02207-3

    Article  CAS  Google Scholar 

  164. Mordmuller B, Szywon K, Greutelaers B, Esen M, Mewono L, Treut C, Murbeth RE, Chilengi R, Noor R, Kilama WL, Imoukhuede EB, Imbault N, Leroy O, Theisen M, Jepsen S, Milligan P, Fendel R, Kremsner PG, Issifou S (2010) Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambarene. Gabon Vaccine 28(41):6698–6703. https://doi.org/10.1016/j.vaccine.2010.07.085

    Article  CAS  Google Scholar 

  165. Belard S, Issifou S, Hounkpatin AB, Schaumburg F, Ngoa UA, Esen M, Fendel R, de Salazar PM, Murbeth RE, Milligan P, Imbault N, Imoukhuede EB, Theisen M, Jepsen S, Noor RA, Okech B, Kremsner PG, Mordmuller B (2011) A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children. PLoS One 6(7):e22525. https://doi.org/10.1371/journal.pone.0022525

    Article  CAS  Google Scholar 

  166. Sirima SB, Mordmuller B, Milligan P, Ngoa UA, Kironde F, Atuguba F, Tiono AB, Issifou S, Kaddumukasa M, Bangre O, Flach C, Christiansen M, Bang P, Chilengi R, Jepsen S, Kremsner PG, Theisen M, Group GMZTS (2016) A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children. Vaccine 34(38):4536–4542. https://doi.org/10.1016/j.vaccine.2016.07.041

    Article  CAS  Google Scholar 

  167. Ogwang C, Kimani D, Edwards NJ, Roberts R, Mwacharo J, Bowyer G, Bliss C, Hodgson SH, Njuguna P, Viebig NK, Nicosia A, Gitau E, Douglas S, Illingworth J, Marsh K, Lawrie A, Imoukhuede EB, Ewer K, Urban BC, Hill AVS, Bejon P, group M. (2015) Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against plasmodium falciparum infection in Kenyan adults. Sci Transl Med 7(286):286re5. https://doi.org/10.1126/scitranslmed.aaa2373

    Article  CAS  Google Scholar 

  168. Mensah VA, Gueye A, Ndiaye M, Edwards NJ, Wright D, Anagnostou NA, Syll M, Ndaw A, Abiola A, Bliss C, Gomis JF, Petersen I, Ogwang C, Dieye T, Viebig NK, Lawrie AM, Roberts R, Nicosia A, Faye B, Gaye O, Leroy O, Imoukhuede EB, Ewer KJ, Bejon P, Hill AV, Cisse B, Group M (2016) Safety, immunogenicity and efficacy of prime-boost vaccination with ChAd63 and MVA encoding ME-TRAP against plasmodium falciparum infection in adults in Senegal. PLoS One 11(12):e0167951. https://doi.org/10.1371/journal.pone.0167951. PubMed PMID: 27978537; PMCID: PMC5158312 applications and patents on malaria vectored vaccines and immunisation regimes including the following (WO2008/122769, Adenoviral vector encoding malaria antigen; and WO 2008/122811 Novel adenovirus vectors). Egeruan Imoukhuede and Ines Petersen were employees of EVI at the time of the study, which supports the development and testing of malaria vaccines. Nicola Viebig is an employee of EVI and Odile Leroy is executive director of EVI. Authors from ReiThera (formerly Okairos) are employees of and/or shareholders in ReiThera, which is developing vectored vaccines for malaria and other diseases. Alfredo Nicosia was employed by ReiThera (formerly Okairos) at the time of the study. There are no further patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors

    Article  CAS  Google Scholar 

  169. Bliss CM, Bowyer G, Anagnostou NA, Havelock T, Snudden CM, Davies H, de Cassan SC, Grobbelaar A, Lawrie AM, Venkatraman N, Poulton ID, Roberts R, Mange PB, Choudhary P, Faust SN, Colloca S, Gilbert SC, Nicosia A, Hill AVS, Ewer KJ (2018) Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP. Sci Rep 8(1):3390. https://doi.org/10.1038/s41598-018-21630-4

    Article  CAS  Google Scholar 

  170. Heppner DG Jr, Kester KE, Ockenhouse CF, Tornieporth N, Ofori O, Lyon JA, Stewart VA, Dubois P, Lanar DE, Krzych U, Moris P, Angov E, Cummings JF, Leach A, Hall BT, Dutta S, Schwenk R, Hillier C, Barbosa A, Ware LA, Nair L, Darko CA, Withers MR, Ogutu B, Polhemus ME, Fukuda M, Pichyangkul S, Gettyacamin M, Diggs C, Soisson L, Milman J, Dubois MC, Garcon N, Tucker K, Wittes J, Plowe CV, Thera MA, Duombo OK, Pau MG, Goudsmit J, Ballou WR, Cohen J (2005) Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of research. Vaccine 23(17–18):2243–2250. https://doi.org/10.1016/j.vaccine.2005.01.142

    Article  CAS  Google Scholar 

  171. Epstein JE, Tewari K, Lyke KE, Sim BK, Billingsley PF, Laurens MB, Gunasekera A, Chakravarty S, James ER, Sedegah M, Richman A, Velmurugan S, Reyes S, Li M, Tucker K, Ahumada A, Ruben AJ, Li T, Stafford R, Eappen AG, Tamminga C, Bennett JW, Ockenhouse CF, Murphy JR, Komisar J, Thomas N, Loyevsky M, Birkett A, Plowe CV, Loucq C, Edelman R, Richie TL, Seder RA, Hoffman SL (2011) Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. Science 334(6055):475–480. https://doi.org/10.1126/science.1211548

    Article  CAS  Google Scholar 

  172. Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, Holman LA, James ER, Billingsley PF, Gunasekera A, Richman A, Chakravarty S, Manoj A, Velmurugan S, Li M, Ruben AJ, Li T, Eappen AG, Stafford RE, Plummer SH, Hendel CS, Novik L, Costner PJ, Mendoza FH, Saunders JG, Nason MC, Richardson JH, Murphy J, Davidson SA, Richie TL, Sedegah M, Sutamihardja A, Fahle GA, Lyke KE, Laurens MB, Roederer M, Tewari K, Epstein JE, Sim BK, Ledgerwood JE, Graham BS, Hoffman SL, Team VRCS (2013) Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341(6152):1359–1365. https://doi.org/10.1126/science.1241800

    Article  CAS  Google Scholar 

  173. Ishizuka AS, Lyke KE, DeZure A, Berry AA, Richie TL, Mendoza FH, Enama ME, Gordon IJ, Chang LJ, Sarwar UN, Zephir KL, Holman LA, James ER, Billingsley PF, Gunasekera A, Chakravarty S, Manoj A, Li M, Ruben AJ, Li T, Eappen AG, Stafford RE, Murshedkar T, DeCederfelt H, Plummer SH, Hendel CS, Novik L, Costner PJ, Saunders JG, Laurens MB, Plowe CV, Flynn B, Whalen WR, Todd JP, Noor J, Rao S, Sierra-Davidson K, Lynn GM, Epstein JE, Kemp MA, Fahle GA, Mikolajczak SA, Fishbaugher M, Sack BK, Kappe SH, Davidson SA, Garver LS, Bjorkstrom NK, Nason MC, Graham BS, Roederer M, Sim BK, Hoffman SL, Ledgerwood JE, Seder RA (2016) Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med 22(6):614–623. https://doi.org/10.1038/nm.4110

    Article  CAS  Google Scholar 

  174. Lyke KE, Ishizuka AS, Berry AA, Chakravarty S, DeZure A, Enama ME, James ER, Billingsley PF, Gunasekera A, Manoj A, Li M, Ruben AJ, Li T, Eappen AG, Stafford RE, Kc N, Murshedkar T, Mendoza FH, Gordon IJ, Zephir KL, Holman LA, Plummer SH, Hendel CS, Novik L, Costner PJ, Saunders JG, Berkowitz NM, Flynn BJ, Nason MC, Garver LS, Laurens MB, Plowe CV, Richie TL, Graham BS, Roederer M, Sim BK, Ledgerwood JE, Hoffman SL, Seder RA (2017) Attenuated PfSPZ vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proc Natl Acad Sci U S A 114(10):2711–2716. https://doi.org/10.1073/pnas.1615324114

    Article  CAS  Google Scholar 

  175. Epstein JE, Paolino KM, Richie TL, Sedegah M, Singer A, Ruben AJ, Chakravarty S, Stafford A, Ruck RC, Eappen AG, Li T, Billingsley PF, Manoj A, Silva JC, Moser K, Nielsen R, Tosh D, Cicatelli S, Ganeshan H, Case J, Padilla D, Davidson S, Garver L, Saverino E, Murshedkar T, Gunasekera A, Twomey PS, Reyes S, Moon JE, James ER, Kc N, Li M, Abot E, Belmonte A, Hauns K, Belmonte M, Huang J, Vasquez C, Remich S, Carrington M, Abebe Y, Tillman A, Hickey B, Regules J, Villasante E, BKL S, Hoffman SL (2017) Protection against plasmodium falciparum malaria by PfSPZ vaccine. JCI Insight 2(1):e89154. https://doi.org/10.1172/jci.insight.89154. PubMed PMID: 28097230; PMCID: PMC5214067 Manoj, D. Padilla, E. Saverino, T. Murshedkar, A. Gunasekera, E.R. James, N. KC, M. Li, Y. Abebe, B.K.L. Sim, and S.L. Hoffman are salaried employees of Sanaria Inc., the developer and owner of PfSPZ Vaccine and the sponsor of the clinical trial. In addition, S.L. Hoffman and B.K.L. Sim have a financial interest in Sanaria Inc

    Article  Google Scholar 

  176. Sissoko MS, Healy SA, Katile A, Omaswa F, Zaidi I, Gabriel EE, Kamate B, Samake Y, Guindo MA, Dolo A, Niangaly A, Niare K, Zeguime A, Sissoko K, Diallo H, Thera I, Ding K, Fay MP, O'Connell EM, Nutman TB, Wong-Madden S, Murshedkar T, Ruben AJ, Li M, Abebe Y, Manoj A, Gunasekera A, Chakravarty S, Sim BKL, Billingsley PF, James ER, Walther M, Richie TL, Hoffman SL, Doumbo O, Duffy PE (2017) Safety and efficacy of PfSPZ vaccine against plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect Dis 17(5):498–509. https://doi.org/10.1016/S1473-3099(17)30104-4

    Article  CAS  Google Scholar 

  177. Jongo SA, Church LWP, Mtoro AT, Chakravarty S, Ruben AJ, Swanson Ii PA, Kassim KR, Mpina M, Tumbo AM, Milando FA, Qassim M, Juma OA, Bakari BM, Simon B, James ER, Abebe Y, Kc N, Saverino E, Fink M, Cosi G, Gondwe L, Studer F, Styers D, Seder RA, Schindler T, Billingsley PF, Daubenberger C, Sim BKL, Tanner M, Richie TL, Abdulla S, Hoffman SL (2019) Increase of dose associated with decrease in protection against controlled human malaria infection by PfSPZ vaccine in Tanzanian adults. Clin Infect Dis. https://doi.org/10.1093/cid/ciz1152

  178. Steinhardt LC, Richie TL, Yego R, Akach D, Hamel MJ, Gutman JR, Wiegand RE, Nzuu EL, Dungani A, Kc N, Murshedkar T, Church LWP, Sim BKL, Billingsley PF, James ER, Abebe Y, Kariuki S, Samuels AM, Otieno K, Sang T, Kachur SP, Styers D, Schlessman K, Abarbanell G, Hoffman SL, Seder RA, Oneko M (2019) Safety, tolerability, and immunogenicity of PfSPZ vaccine administered by direct venous inoculation to infants and young children: findings from an age de-escalation, dose-escalation double-blinded randomized, controlled study in western Kenya. Clin Infect Dis. https://doi.org/10.1093/cid/ciz925

  179. Roestenberg M, Teirlinck AC, McCall MB, Teelen K, Makamdop KN, Wiersma J, Arens T, Beckers P, van Gemert G, van de Vegte-Bolmer M, van der Ven AJ, Luty AJ, Hermsen CC, Sauerwein RW (2011) Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 377(9779):1770–1776. https://doi.org/10.1016/S0140-6736(11)60360-7

    Article  CAS  Google Scholar 

  180. Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, van de Vegte-Bolmer M, van Schaijk B, Teelen K, Arens T, Spaarman L, de Mast Q, Roeffen W, Snounou G, Renia L, van der Ven A, Hermsen CC, Sauerwein R (2009) Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 361(5):468–477. https://doi.org/10.1056/NEJMoa0805832

    Article  CAS  Google Scholar 

  181. Mordmuller B, Surat G, Lagler H, Chakravarty S, Ishizuka AS, Lalremruata A, Gmeiner M, Campo JJ, Esen M, Ruben AJ, Held J, Calle CL, Mengue JB, Gebru T, Ibanez J, Sulyok M, James ER, Billingsley PF, Natasha KC, Manoj A, Murshedkar T, Gunasekera A, Eappen AG, Li T, Stafford RE, Li M, Felgner PL, Seder RA, Richie TL, Sim BK, Hoffman SL, Kremsner PG (2017) Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature 542(7642):445–449. https://doi.org/10.1038/nature21060

    Article  CAS  Google Scholar 

  182. Walk J, Reuling IJ, Behet MC, Meerstein-Kessel L, Graumans W, van Gemert GJ, Siebelink-Stoter R, van de Vegte-Bolmer M, Janssen T, Teelen K, de Wilt JHW, de Mast Q, van der Ven AJ, Diez Benavente E, Campino S, Clark TG, Huynen MA, Hermsen CC, Bijker EM, Scholzen A, Sauerwein RW (2017) Modest heterologous protection after plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial. BMC Med 15(1):168. https://doi.org/10.1186/s12916-017-0923-4

    Article  CAS  Google Scholar 

  183. Jongo SA, Urbano V, Church LWP, Olotu A, Manock SR, Schindler T, Mtoro A, Kc N, Hamad A, Nyakarungu E, Mpina M, Deal A, Bijeri JR, Ondo Mangue ME, Ntutumu Pasialo BE, Nguema GN, Owono SN, Rivas MR, Chemba M, Kassim KR, James ER, Stabler TC, Abebe Y, Saverino E, Sax J, Hosch S, Tumbo AM, Gondwe L, Segura JL, Falla CC, Phiri WP, Hergott DEB, Garcia GA, Schwabe C, Maas CD, Murshedkar T, Billingsley PF, Tanner M, Ayekaba MO, Sim BKL, Daubenberger C, Richie TL, Abdulla S, Hoffman SL (2021) Immunogenicity and protective efficacy of radiation-attenuated and chemo-attenuated PfSPZ vaccines in Equatoguinean adults. Am J Trop Med Hyg. 104(1):283–293. https://doi.org/10.4269/ajtmh.20-0435

    Article  CAS  Google Scholar 

  184. Spring M, Murphy J, Nielsen R, Dowler M, Bennett JW, Zarling S, Williams J, de la Vega P, Ware L, Komisar J, Polhemus M, Richie TL, Epstein J, Tamminga C, Chuang I, Richie N, O'Neil M, Heppner DG, Healer J, O'Neill M, Smithers H, Finney OC, Mikolajczak SA, Wang R, Cowman A, Ockenhouse C, Krzych U, Kappe SH (2013) First-in-human evaluation of genetically attenuated plasmodium falciparum sporozoites administered by bite of anopheles mosquitoes to adult volunteers. Vaccine 31(43):4975–4983. https://doi.org/10.1016/j.vaccine.2013.08.007

    Article  Google Scholar 

  185. Kublin JG, Mikolajczak SA, Sack BK, Fishbaugher ME, Seilie A, Shelton L, VonGoedert T, Firat M, Magee S, Fritzen E, Betz W, Kain HS, Dankwa DA, Steel RW, Vaughan AM, Noah Sather D, Murphy SC, Kappe SH (2017) Complete attenuation of genetically engineered plasmodium falciparum sporozoites in human subjects. Sci Transl Med 9(371). https://doi.org/10.1126/scitranslmed.aad9099

  186. Roestenberg M, Walk J, van der Boor SC, Langenberg MCC, Hoogerwerf MA, Janse JJ, Manurung M, Yap XZ, Garcia AF, Koopman JPR, Meij P, Wessels E, Teelen K, van Waardenburg YM, van de Vegte-Bolmer M, van Gemert GJ, Visser LG, van der Ven A, de Mast Q, Natasha KC, Abebe Y, Murshedkar T, Billingsley PF, Richie TL, Sim BKL, Janse CJ, Hoffman SL, Khan SM, Sauerwein RW (2020) A double-blind, placebo-controlled phase 1/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1. Sci Transl Med 12(544). https://doi.org/10.1126/scitranslmed.aaz5629

  187. Datoo MSMNHS A, Traoré O, Rouamba T, Bellamy D, Yameogo P, Valia D, Tegneri M, Ouedraogo F, Soma R, Sawadogo S, Sorgho F, Derra K, Rouamba E, Orindi B, Ramos-Lopez F, Flaxman A, Cappuccini F, Kailath R, Elias S, Mukhopadhyay E, Noe A, Cairns M, Lawrie A, Roberts R, Valéa I, Sorgho H, Williams N, Glenn G, Fries L, Reimer J, Ewer KJ, Shaligram U, Hill AVS, Tinto H (2021) High efficacy of a low dose candidate Malaria vaccine, R21 in 1 adjuvant matrix-M™, with seasonal administration to children in Burkina Faso. Lancet preprint. https://doi.org/10.2139/ssrn.3830681

Books and Reviews

  • Beeson JG, Kurtovic L, Dobaño C, Opi DH, Chan JA, Feng G, Good MF, Reiling L, Boyle MJ (2019) Challenges and strategies for developing efficacious and long-lasting malaria vaccines. Sci Transl Med 11(474):eaau1458

    Article  CAS  Google Scholar 

  • Birkett AJ, Moorthy VS, Loucq C, Chitnis CE, Kaslow DC (2013) Malaria vaccine R&D in the decade of vaccines: breakthroughs, challenges and opportunities. Vaccine 18(31 Suppl 2):B233–B243

    Article  Google Scholar 

  • Bruder JT, Angov E, Limbach KJ, Richie TL (2010) Molecular vaccines for malaria. Hum Vaccin 6:54–77

    Article  CAS  Google Scholar 

  • Desowitz RS (1991) The malaria capers: more tales of parasites and people, research and reality. Norton, New York

    Google Scholar 

  • Dinglasan RR, Jacobs-Lorena M (2008) Flipping the paradigm on malaria transmission-blocking vaccines. Trends Parasitol 24:364–370

    Article  CAS  Google Scholar 

  • Draper SJ, Angov E, Horii T, Miller LH, Srinivasan P, Theisen M, Biswas S (2015) Recent advances in recombinant protein-based malaria vaccines. Vaccine 33(52):7433–7443

    Article  CAS  Google Scholar 

  • Duffy PE, Sahu T, Akue A, Milman N, Anderson C (2012) Pre-erythrocytic malaria vaccines: identifying the targets. Expert Rev Vaccines 11(10):1261–1280

    Article  CAS  Google Scholar 

  • Duffy PE, Gorres JP (2020) Malaria vaccines since 2000: progress, priorities, products. NPJ Vaccines 5(1):48

    Article  Google Scholar 

  • Heppner DG (2013) The malaria vaccine–status quo 2013. Travel Med Infect Dis 11(1):2–7

    Article  Google Scholar 

  • Good MF, Stanisic DI (2020) Whole parasite vaccines for the asexual blood stages of plasmodium. Immunol Rev 293(1):270–282

    Article  CAS  Google Scholar 

  • Hill AV, Reyes-Sandoval A, O'Hara G, Ewer K, Lawrie A, Goodman A, Nicosia A, Folgori A, Colloca S, Cortese R, Gilbert SC, Draper SJ (2010) Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin 6:78–83

    Article  CAS  Google Scholar 

  • Hoffman SL, Vekemans J, Richie TL, Duffy PE (2015) The march toward malaria vaccines. Vaccine 33(Suppl 4):D13–D23

    Article  CAS  Google Scholar 

  • Hviid L (2010) The role of plasmodium falciparum variant surface antigens in protective immunity and vaccine development. Hum Vaccin 6:84–89

    Article  CAS  Google Scholar 

  • Itsara LS, Zhou Y, Do J, Grieser AM, Vaughan AM, Ghosh AK (2018) The development of whole Sporozoite vaccines for plasmodium falciparum Malaria. Front Immunol 9:2748

    Article  CAS  Google Scholar 

  • Langhorne J, Ndungu FM, Sponaas AM, Marsh K (2008) Immunity to malaria: more questions than answers. Nat Immunol 9:725–732

    Article  CAS  Google Scholar 

  • Miura K (2016) Progress and prospects for blood-stage malaria vaccines. Expert Rev Vaccines 15(6):765–781

    Article  CAS  Google Scholar 

  • Moorthy VS, Kieny MP (2010) Reducing empiricism in malaria vaccine design. Lancet Infect Dis 10:204–211

    Article  Google Scholar 

  • Nikolaeva D, Draper SJ, Biswas S (2015) Toward the development of effective transmission-blocking vaccines for malaria. Expert Rev Vaccines 14(5):653–680

    Article  CAS  Google Scholar 

  • Ntege EH, Takashima E, Morita M, Nagaoka H, Ishino T, Tsuboi T (2017) Blood-stage malaria vaccines: post-genome strategies for the identification of novel vaccine candidates. Expert Rev Vaccines 16(8):769–779

    Article  CAS  Google Scholar 

  • Ouattara A, Barry AE, Dutta S, Remarque EJ, Beeson JG, Plowe CV (2015) Designing malaria vaccines to circumvent antigen variability. Vaccine 33(52):7506–7512

    Article  CAS  Google Scholar 

  • Ouattara A, Laurens MB (2015) Vaccines against malaria. Clin Infect Dis 60(6):930–936

    Article  CAS  Google Scholar 

  • Richards JS, Beeson JG (2009) The future for blood-stage vaccines against malaria. Immunol Cell Biol 87:377–390

    Article  CAS  Google Scholar 

  • Shah S (2010) The fever: how malaria has ruled humankind for 500,000 years. Farrar, Straus and Giroux, New York

    Google Scholar 

  • Sherwin IW (2009) The elusive malaria vaccine: miracle or mirage? ASM Press, Washington, DC

    Book  Google Scholar 

  • Stanisic DI, Good MF (2015) Whole organism blood stage vaccines against malaria. Vaccine 33(52):7469–7475

    Article  Google Scholar 

  • Stanisic DI, McCarthy JS, Good MF (2017) Controlled human Malaria infection: applications, advances, and challenges. Infect Immun 86(1):e00479–e00417

    Google Scholar 

  • Steel RW, Kappe SH, Sack BK (2016) An expanding toolkit for preclinical pre-erythrocytic malaria vaccine development: bridging traditional mouse malaria models and human trials. Future Microbiol 11(12):1563–1579

    Article  CAS  Google Scholar 

  • Vaughan AM, Wang R, Kappe SH (2010) Genetically engineered, attenuated whole-cell vaccine approaches for malaria. Hum Vaccin 6:107–113

    Article  CAS  Google Scholar 

  • Wykes M, Good MF (2007) A case for whole-parasite malaria vaccines. Int J Parasitol 37:705–712

    Article  CAS  Google Scholar 

Download references

Acknowledgments

CVP’s malaria vaccine work has been supported by the National Institute of Allergy and Infectious Diseases of the US National Institutes of Health, the US Department of Defense, the Doris Duke Charitable Foundation, and by the Howard Hughes Medical Institute. MBL’s malaria vaccine work has been supported by the National Institute of Allergy and Infectious Diseases of the US National Institutes of Health, the U.S. Department of Defense, the Howard Hughes Medical Institute, the Maryland Industrial Partnerships Program, and the Bill and Melinda Gates Foundation. The authors acknowledge the US Agency for International Development, the Walter Reed Army Institute of Research, GlaxoSmithKline Biologicals, Sanaria Inc., the US Military Malaria Vaccine Program—Naval Medical Research Center, the Malaria Research and Training Center of the University of Bamako, Mali, and the Center National de Recherche et de Formation sur le Paludisme and the Groupe de Recherche Action en Santé, both of Ouagadougou, Burkina Faso, for collaboration on malaria vaccine trials.

Author information

Authors and Affiliations

  1. Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA

    Matthew B. Laurens & Christopher V. Plowe

Authors
  1. Matthew B. Laurens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher V. Plowe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew B. Laurens .

Editor information

Editors and Affiliations

  1. Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

    Lester M Shulman

Section Editor information

  1. Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

    Lester M. Shulman

  2. Central Virology Laboratory, Laboratory of Environmental Virology, Sheba Medical Center, Public Health Services, Israel Ministry of Health, Tel Aviv, Israel

    Lester M. Shulman

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer Science+Business Media, LLC, part of Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Laurens, M.B., Plowe, C.V. (2023). Malaria Vaccines. In: Shulman, L.M. (eds) Infectious Diseases. Encyclopedia of Sustainability Science and Technology Series. Springer, New York, NY. https://doi.org/10.1007/978-1-0716-2463-0_536

Download citation

Publish with us

Policies and ethics

Search

Navigation